Global Blood Therapeutics Inc is categorized under Biological Research in San Francisco, CA and active since 2011.
Global Blood Therapeutics Inc was established in 2011, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Biological Research business, which does work in the B2B market, and is classified as a Biological Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Mark A Goldsmith at the company’s single location by writing to 55 Mission St, San Francisco, California CA 94105 or by phoning (415) 766-3600. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Global Blood Therapeutics Inc |
| Contact Person: | Mark A Goldsmith |
| Address: | 55 Mission St, San Francisco, California 94105 |
| Phone Number: | (415) 766-3600 |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Founded: | 2011 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Biological Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Global Blood Therapeutics Inc was started in 2011 to provide professional Biological Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Mark A Goldsmith for inquiries that concern Global Blood Therapeutics Inc by calling the company number (415) 766-3600, as your correspondence is most welcome. Additionally, the physical location of the single location of Global Blood Therapeutics Inc can be found at the coordinates 37.792901,-122.393389 as well as the street address 55 Mission St in San Francisco, California 94105.
For its online presence, you may visit Global Blood Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.